&#xa0;
[normal]&#xa0;
[normal]Written evidence [bold]from the British Society for Rheumatology[bold] (LTC 88)[bold]The British Society for Rheumatology (BSR)
[normal] exists to promote excellence in the treatment of people with arthritis and musculoskeletal conditions and to support those delivering it.
[normal] 
[normal]As a professional association representing those 
[normal]specialising
[normal] in 
[normal]rheumatic and 
[normal]musculoskeletal conditions, BSR aims to improve standards of care in rheumatology. 
[normal]The BSR welcomes the opportunity to contribute to thi
[normal]s timely
[normal], necessary
[normal] and important inquiry.
[normal]&#xa0;
[normal]Key Points:
[normal]&#xa0;
[normal]The impact of rheumatic disease[bold]1.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]Rheumatology is a multidisciplinary branch of medicine that deals with the investigation, diagnosis and management of patients with rheumatic diseases and other musculoskeletal conditions.[bold] This incorporates over 200 disorders affecting joints, muscles and soft tissues, including autoimmune disorders and spinal pain. A significant number of rheumatic conditions also affect other organ systems
[normal]. 
[normal]&#xa0;
[normal]2.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]Rheumatic diseases are[bold] often[bold] under-prioritise[bold]d,[bold] in part due to low levels of 
[normal]public 
[normal]awareness about
[normal] what rheumatology is
[normal].
[normal] 
[normal]A recent survey
[normal] conducted by the 
[normal]American
[normal] C
[normal]ollege of Rheumatology indicated
[normal] 
[normal]that the word ‘Rheumatology’ is for the majority of public participants not known
[normal]. For others it was commonly associated with
[normal] foot doctors/podiatry
[normal], or viewed solely as an issue relating to old age
[normal].
[normal] In the UK, the low profile of rheumatology is reflected in the fact that it is only mentioned once in the Department of Health
[normal]’s Long Term Conditions C
[normal]ompendium
[normal].
[normal]&#xa0;
[normal]3.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]Despite[bold] low awareness, m[bold]usculoskeletal conditions [bold]are the[bold] the single biggest cause of disability[bold],[bold] accounting for 31% of the total 
[normal]UK
[normal] burden
[normal]. I
[normal]n contrast 
[normal]to 
[normal]encouraging 
[normal]improvement
[normal] trends for 
[normal]premature mortality
[normal], the 
[normal]UK
[normal] trend for 
[normal]chronic 
[normal]disability burden is getting worse. 
[normal]I
[normal]n a rece
[normal]nt international comparison of 
[normal]disability adjusted life years in 
[normal]developed countries with similar economies, the UK 
[normal]ranks a mere 16
[normal] out of 19 for 
[normal]osteoarthritis, and 15 out of 19 for low back pain
[normal] 
[normal]. C
[normal]oupled w
[normal]ith the 
[normal]known health service 
[normal]challenge
[normal] of an a
[normal]geing population
[normal], it is therefore vital to reverse the trend of avoidable disability through the quality improvement of rheumatology services
[normal].
[normal]&#xa0;
[normal]4.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]A key issue to address is the collection of data, which has [bold]failed to evolve[bold] over time[bold] to take account of the t[bold]ransformation in[bold] [bold]rheumatology treatment[bold] options.[bold] Patients with rheumatic disease 
[normal]used to 
[normal]occupy
[normal] a great number of
[normal] hospital 
[normal]beds;
[normal] however
[normal] drug therapy now allows the provision to be largely ambulatory
[normal]. 
[normal]Commissioners therefore have little to inform 
[normal]their service specifications, and
[normal] there is insufficient
[normal] public health epidemiology data 
[normal]to inform Joint Strategic Needs Assessments.
[normal] 
[normal]The fact there are over 200 conditions can
[normal] further
[normal] hinder understanding and therefore the BSR has created a simpler domain and pathway app
[normal]roach. 
[normal]&#xa0;
[normal]5.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]Although rheumatology services 
[normal]no longer
[normal] 
[normal]services are no longer mainly inpatient rehabilitation services
[normal] involving
[normal] hospital
[normal] admission, the p
[normal]otential 
[normal]for 
[normal]Quality, Innovation, Productivity and Prevention ([bold]QIPP[bold])[bold] savings[bold] [bold]remain[bold] significant[bold], as [bold]£680m was spent on drug therapy in England alone in 2012[bold].[bold] [bold]S
[normal]avings come from treating people to NICE and national standards and early diagnosis and intervention, and include
[normal]:
[normal]6.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]Below we outline some examples [bold]in which[bold] [bold]rheumatology [bold]services have been configured to offer the patient benefits and reduced costs[bold] outlined above.
[normal] 
[normal]However service provision remains varied throughout the 
[normal]UK; the challenge is therefore to enable the delivery of consistently excellent services.
[normal]Early intervention and [bold]the [bold]integrated care[bold] patient pathway[bold]7.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]Unlike other services which can be wholly community-based, effective 
[normal]rheumatology services require [bold]integrated care along the whole patient pathway[bold],[bold] [bold]across secondary, [bold]community and primary ca[bold]re[bold]. This is 
[normal]due to
[normal] 
[normal]the 
[normal]diag
[normal]nostic
[normal] 
[normal]infrastructure required, and the complexity of autoimmune diseases which can affect multiple organ systems
[normal].
[normal] 
[normal]&#xa0;
[normal]8.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]Wherever rheumatology services are delivered
[normal],
[normal] there needs to be 
[normal]an 
[normal]extensive[bold] 
[normal]diagnostics infrastructure in place[bold] incorporating MRI, ultrasound/X-ray and complex blood testing
[normal].
[normal] 
[normal]Unless there is a major investment in community diagnostic centres, 
[normal]this will continue to be provided in acute or community hospital settings.
[normal] 
[normal]The benefit of having these diagnostic tools in a ‘one-stop shop’ is that the patient avoids the inconve
[normal]nience of multiple appointments 
[normal](and
[normal] associated multiple costs
[normal]) and
[normal] the crucial time period from symptom onset to treatment is minimised. 
[normal]&#xa0;
[normal]9.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]Early intervention[bold] is [bold]clinically[bold] significant in rheumatology. Up to three months after symptom onset, rheumatic diseases can be treated effectively[bold] (to a low level or remission)[bold] with relatively inexpensive disease-modifying [bold]antirheumatic [bold]drugs (DMARDS). [bold]A treatment delay of more than three months can result in a more aggressive course to the disease which 
[normal]causes long term damage to joints, and
[normal] require
[normal]s
[normal] expensive biologic treatments.
[normal]&#xa0;
[normal]10.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]Although the NICE guideline requires that
[normal] patie
[normal]nts are put onto DMARDs within three
[normal] months of symptom onset
[normal], a 
[normal]NAO report in 2009 
[normal]found that this happens with only 10% of patients
[normal].
[normal] This is in part due to delays in being seen by a rheumatologist and partly due to local differences in the access level to key drugs.
[normal] The average delay in the UK in GP surgeries is around nine months, by which time joint damage in aggressive disease has already occurred.
[normal]&#xa0;
[normal]11.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]The same report concluded that
[normal] o
[normal]nly 63% of patients in acute trusts provided annual review for Rheumatoid Arthritis patients to monitor disease progression a
[normal]nd emergence of co-morbidities.
[normal] This indicates that 
[normal]there is some way to go in integrating [bold]care[bold] for ongoing management of patients with rheumatic disease, as well as initial diagnosis and treatment[bold].
[normal]&#xa0;
[normal]12.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]The significance of this is 
[normal]shown
[normal] in a recent National Rheumatoid Arthritis Society
[normal] (NRAS)
[normal] recently report
[normal]5
[normal] that highlights the range and impact of comorbidities associated with rheumatoid arthritis, and demonstrates the extent to which rheumatology services 
[normal]need to
[normal] be linked to other specialist and community services in a coordinated and holistic manner. Key points from this report include the following:
[normal]13.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]Most
[normal] financial incentives for good practice in 
[normal]the current system
[normal] only focus on parts of the pathway – 
[normal]discreet
[normal] pieces of care as opposed to the whole 
[normal]patient care package
[normal]. 
[normal]This approach is a key system barrier to the principle of integrated care.
[normal]Commissioner support, and best practice examples[bold]14.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]The BSR
[normal] have joined
[normal] with Arthritis Care and 
[normal]NRAS
[normal] 
[normal]to 
[normal]form the Rheumatology Commissioning Support 
[normal]Alliance – a project funded by the 
[normal]Department of Health
[normal] to 
[normal]support commissioners and develop tools to demonstrate how better services for patients and better value for the NHS can both result from a more service-user-centred approach.
[normal] 
[normal]&#xa0;
[normal]15.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]The BSR has also recently launched a Commissioning Toolkit for Providers
[normal]. This package aims to help rheumatology professionals develop their knowledge and skills to design effective services and make the most of commissioning opportunities.
[normal]&#xa0;
[normal]16.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]In addition to the initiatives above, 
[normal]the BSR is proactively developing a hub [bold]of good practice service models[bold]. We intend to publish case studies in the 
[normal]autumn
[normal], however in advance of this we outline two models
[normal] below
[normal] that give a flavour of current initia
[normal]tives being delivered in the UK
[normal].
[normal]&#xa0;
[normal]17.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]Site A example
[normal] :
[normal]18.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]Site A outcome: reduced work loss due to depression and anxiety[bold],[bold] and [bold]40% reduction in the[bold] need to [bold]use[bold] expensive biologic[bold] drugs.[bold]&#xa0;
[normal]19.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]Site B
[normal] example:
[normal]20.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]Site B outcome: Savings of over a quarter of a million pounds per year over the last three years. These are shared between [bold]the [bold]commissioner and provider.[bold]&#xa0;[bold]21.
[normal]&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
[normal]The BSR is happy to
[normal] [bold]expand further on any of the points raised in this submission.
[normal]May 2013
[normal] BSR website: http://www.rheumatology.org.uk/
[normal] Third Edition Long Term Conditions Compendium, Department of Health (May 2012): https://www.gov.uk/government/news/third-edition-of-long-term-conditions-compendium-published
[normal] UK health performance: findings of the Global Burden of Disease study 2010: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60355-4/abstract
[normal]NICE guideline for rheumatoid arthritis: http://publications.nice.org.uk/rheumatoid-arthritis-cg79
[normal] NRAS ‘The Impact of Rheumatoid Arthritis Co-morbidities’ December 2012: http://www.nras.org.uk/includes/documents/cm_docs/2012/t/1_the_impact_of_rheumatoid_arthritis_comorbidities_final_pdf_pdf.pdf
[normal] NAO rheumatoid arthritis report 2009: http://www.nao.org.uk/report/services-for-people-with-rheumatoid-arthritis/
[normal] BSR Commissioning toolkit, March 2013: http://www.rheumatology.org.uk/about_bsr/press_releases/commissioning_toolkit_launched.aspx
[normal]